Field trials were conducted at 3 locations and involved 363 calves with spontaneously occurring bovine respiratory disease (BRD). Treatments consisted of flunixin meglumine plus antibiotic (oxytetracycline) (n=181) compared to antibiotic (oxytetracycline) alone (n=182). In both instances, antibiotic was administered at 10 mg/kg (4.5 mg/lb) IM for 3 consecutive days. FM was administered IV at 2.2 mg/kg for 1 to 3 days depending on the temperature response after each treatment. FM dosing was repeated when the animals' temperature was above 104+°F. Animals were monitored for 7 additional days following the last antibiotic treatment on day 3.
Parameters included: temperature, character of respiration, depression, illness index score, mortality and treatment failure.
In conclusion, flunixin meglumine ameliorated some of the clinical signs of bovine respiratory disease and demonstrated efficacy as an antipyretic.
A field trial with 81 male Holstein calves compared treatment with FM and OTC to OTC alone. FM was dosed once daily at 2.2 mg/kg (1.0 mg/lb) IV for 1 to 3 days and OTC once daily at 10 mg/kg (4.5 mg/lb). Animals with acute signs of pneumonia (rectal temperature greater than 104+°F and respiratory rate greater than 40) were randomly assigned to one of two treatment groups. FM was repeated in calves with temperatures over 104+°F on days 2 and 3.
In conclusion, flunixin ameliorated some of the clinical signs of bovine respiratory disease and demonstrated efficacy as an antipyretic.